As the largest pharma and tech suppliers - from Novartis to GE Healthcare to Thermo Fisher - begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients' research models. The technology allows scientists to more easily disable genes or change their function by replacing DNA sequences.